Skip to main content
. 2020 Jul 7;4(13):3093–3101. doi: 10.1182/bloodadvances.2020001987

Figure 3.

Figure 3.

VWF activity as measured by a VWF:GP1bM activity assay on the first and second day after caplacizumab administration. Patients were on an alternate-day caplacizumab treatment regimen and closely monitored for signs of relapse. Normal range for VWF activity, 50% to 187%. LL, lower limit of normal; UL, upper limit of normal.